Antiemetics: American Society of Clinical Oncology clinical practice guideline update
E Basch, AA Prestrud, PJ Hesketh, MG Kris… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To update the American Society of Clinical Oncology (ASCO) guideline for
antiemetics in oncology. Methods A systematic review of the medical literature was …
antiemetics in oncology. Methods A systematic review of the medical literature was …
Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus …
F Roila, J Herrstedt, M Aapro, RJ Gralla… - Annals of …, 2010 - annalsofoncology.org
Despite the relevant progress achieved in the last 20 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in …
F Roila, A Molassiotis, J Herrstedt, M Aapro… - Annals of …, 2016 - annalsofoncology.org
Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
[HTML][HTML] ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini… - Annals of oncology, 2012 - Elsevier
Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …
Western countries. Although screening programmes including the implementation of faecal …
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical …
K Aogi, H Takeuchi, T Saeki, K Aiba, K Tamura… - International Journal of …, 2021 - Springer
Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …
Biological and pharmacological aspects of the NK1‐receptor
S Garcia-Recio, P Gascón - BioMed research international, 2015 - Wiley Online Library
The neurokinin 1 receptor (NK‐1R) is the main receptor for the tachykinin family of peptides.
Substance P (SP) is the major mammalian ligand and the one with the highest affinity. SP is …
Substance P (SP) is the major mammalian ligand and the one with the highest affinity. SP is …
[HTML][HTML] Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K Jordan, F Jahn, M Aapro - Annals of Oncology, 2015 - Elsevier
The prevention of chemotherapy-induced nausea and vomiting (CINV) has been
revolutionized over the past 25 years. Guideline-based treatment means that vomiting can …
revolutionized over the past 25 years. Guideline-based treatment means that vomiting can …
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice
K Jordan, R Gralla, F Jahn, A Molassiotis - European journal of …, 2014 - Elsevier
Over the past decades major improvements in the management of chemotherapy induced
nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV …
nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV …
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or …
LS Schwartzberg, MR Modiano, BL Rapoport… - The Lancet …, 2015 - thelancet.com
Background Chemotherapy-induced nausea and vomiting is a common side-effect of many
antineoplastic regimens and can occur for several days after treatment. We aimed to assess …
antineoplastic regimens and can occur for several days after treatment. We aimed to assess …
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …
S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …